Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Small Cell Lung Carcinoma 3Thrombocytosis 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neuroendocrine Tumors 1Lymphoma, Non-Hodgkin 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1EGFR Positive Non-small Cell Lung Cancer 1Carcinosarcoma 1

Interventions

Paclitaxel 95Carboplatin 77pembrolizumab 74Cisplatin 29Bevacizumab 27Letrozole 22Radiotherapy 21Doxorubicin 21Megestrol Acetate 20lenvatinib 19olaparib 18Taxes 17Docetaxel 17Nivolumab 16Specimen Handling 15Metformin 15dostarlimab 14Magnetic Resonance Spectroscopy 14Gemcitabine 13durvalumab 12Medroxyprogesterone Acetate 12Trastuzumab 11Indocyanine Green 11Fulvestrant 11Biopsy 11temsirolimus 10abemaciclib 10atezolizumab 9Radiation 9Early Intervention, Educational 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Endometrial Neoplasms × pelcitoclax × Clear all
NCT05691504 2026-05-13

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

National Cancer Institute (NCI)

Phase 1 Active not recruiting
42 enrolled
GynecologicSarcoma

Carcinosarcoma, Fallopian Tube Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡